At the recent IMPAKT Breast Cancer Conference, 2 – 4th May, Brussels, ecancer´s Peter Goodwin talks to Ana Vivancos about her pioneering research in cancer genomics and work contributing to improved phase I clinical studies and best therapies for patients.
Related Posts
The Translational Biomedicine and Oncology Research Consortium has been created
It is the first National Agreement that includes the Academic environment, basic research, clinical research and the pharmaceutical industry
07 Sep 2010
International Workshop Stimulates New Ideas in Cancer Research and Therapy, March 04 – 05, 2013, Boston
The Mass General Cancer Center hosted an international, multi-disciplinary workshop on March 4 and 5 to explore how advances in…
13 Mar 2013
International consortium trailblazing the genomic classification of colorectal cancer through big data
Barcelona, October 12, 2015.– A major collaborative study carried out through an international consortium of excellence has, for the very…
14 Oct 2015
A new treatment improves the survival rates of patients with metastatic breast cancer
• The findings of the study, headed by the Breast Cancer Group at the VALL D’HEBRON ONCOLOGY INSTITUTE (VHIO) in Barcelona, present a new treatment option for patients with metastatic breast cancer.
• Eribulin is the first drug in the last 10 years to have an impact on metastatic breast cancer survival rates without having to be combined.
• The drug improves survival rates by 20% and has a very good toxicity profile compared to other chemotherapy drugs.
• The objective of the Phase III clinical trial was to identify the efficacy of a new treatment strategy for metastatic breast cancer.
03 Mar 2011
European cancer centers of excellence: powering long-term collaborative partnerships.
For many decades, cancer research in Europe has been heavily fragmented, inefficient and duplicating work. Now, long-term collaborations have been…
11 Dec 2015
VHIO genomic study identifies subgroups of HER2+ breast cancer with varying sensitivities to anti-HER2 treatment
• VHIO describes as many as four subgroups of HER2+ breast cancer (Luminal A, Luminal B, HER2-enriched and Basal-Like) with…
17 Jan 2014
VHIO´s Joan Seoane awarded with second ERC Grant to translate frontier cancer research into improved treatments for patients
• The latest round of ERC ´Proof of Concept´ Grants will further support existing ERC grant holders to advance research…
06 Feb 2015
Medical research safeguarded in Europe
ESMO welcomes the adoption of the Clinical Trials Regulation by the European Union Source: The European Society for Medical Oncology…
16 Jun 2014
2012 Fero Foundation Grant to support the study of genetic alterations in advanced colon cancer towards personalized medicine
21 May 2012, Barcelona – Héctor G. Palmer, Principal Investigator of the Stem Cells and Cancer Group at the Vall…
24 May 2012
Global leader in oncology José Baselga awarded the ESMO Lifetime Achievement Award for his crucial role in drug development against breast cancer
Announced today by the European Society for Medical Oncology (ESMO), this year´s highly prestigious ESMO Lifetime Achievement Award honors the…
20 Jul 2017
Affordable funding increase can save three million lives per year from cancer in low- and middle-income countries (LMICs) by 2030
Source: Union for International Cancer Control (UICC) New data projects that US$18 billion increase in funding per year by the…
04 Feb 2015
Academy recognition of VHIO´s Director, Josep Tabernero, for his exceptional leadership and contribution to medical oncology, cancer science, and patient care
Announced this week, Josep Tabernero, Director of VHIO, Head of the Medical Oncology Service of the Vall d´Hebron University Hospital…
16 Feb 2017
The ”la Caixa” Banking Foundation pays homage to medical researchers
Source: the ”la Caixa” Banking Foundation Josep Baselga, María Blasco, Valentí Fuster, Maite Mendioroz, Eduard Gratacós, Bonaventura Clotet and Pedro…
06 Sep 2017
VHIO´s next Meet the Editors with Nature Medicine
Nature Medicine´s Senior Editor, Vicotria Aranda will come to VHIO Monday 17 September 2012 to deliver the 4th in the prestigious series of VHIO Meet the Editors talks.
28 Jun 2012
VHIO´s Rodrigo Dienstmann receives Grant for Oncology Innovation powered by Merck
Officially announced during last month´s European Cancer Congress, 25 – 29 September in Vienna, Austria, Rodrigo Dienstmann, Principal Investigator of…
16 Oct 2015
